American firm spends $250M on employee obesity programs
An American company spends over $250 million annually on treating employee obesity with GLP-1 medications such as Ozempic and Wegovy, which the CEO considers an investment in long-term health. This expenditure accounts for about 13% of the company's total healthcare costs, which amount to more than $2 billion annually for approximately 211,000 employees. As demand for obesity and diabetes medications increases, the share of these drugs in health claims has risen to 11.4% by 2026, influencing corporate decisions regarding insurance coverage.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)